Table 5.

Patients main characteristics and results of pooled data from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, NCT02637687).

Reference	79
Patient (n)	29
Median age	60 years (2 children)
Histological subtype [n (%)] PTC FTC ATC	20 (69%) 2 (7%) 7 (24%)
mPFS	10.8 vs 5.8
ORR PTC/FTC ATC	71% (95% CI 51-87) 29% (95% CI 4-71)
TTR	1.87 months
mPFS	69%
OS	76%
AEs	Grade 1-2
DCR (24 weeks) PTC/FTC ATC	91% (95% CI 71-99) 29% (95% CI 4-71)

AE, adverse event; ATC, anaplastic thyroid cancer; CR, complete response; DCR, disease control rate; FTC, follicular thyroid cancer; mPFS, median progression-free survival; ORR: objective response rate; OS, overall survival; PD, progressive disease; PTC, papillary thyroid cancer; TTP, time to treatment failure.